- 全部删除
您的购物车当前为空
SIRT5 inhibitor 7 (compound 58) 是底物竞争性和选择性的 SIRT5 抑制剂,IC 50 = 310 nM,显著减轻了脂多糖(LPS)和盲肠结扎/穿孔(CLP)诱导的脓毒性AKI小鼠的肾功能障碍和病理损伤,调节急性肾损伤(AKI)小鼠肾脏中蛋白琥珀酰化和促炎细胞因子的释放。

SIRT5 inhibitor 7 (compound 58) 是底物竞争性和选择性的 SIRT5 抑制剂,IC 50 = 310 nM,显著减轻了脂多糖(LPS)和盲肠结扎/穿孔(CLP)诱导的脓毒性AKI小鼠的肾功能障碍和病理损伤,调节急性肾损伤(AKI)小鼠肾脏中蛋白琥珀酰化和促炎细胞因子的释放。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 11,700 | In stock |
SIRT5 inhibitor 7 相关产品
| 产品描述 | SIRT5 inhibitor 7 (compound 58), a substrate-competitive and selective SIRT5 inhibitor with IC 50 = 310 nM, significantly attenuated renal dysfunction and pathological damage in lipopolysaccharide (LPS)- and cecum ligation/perforation (CLP)-induced septic AKI mice, and modulated proteinsuccinimidylation and proinflammatory cytokine release and pro-inflammatory cytokine release in the kidneys of acute kidney injury (AKI) mice. |
| 靶点活性 | SIRT5:310 nM |
| 体外活性 | SIRT5 inhibitor 7 是一种高效的 SIRT5 抑制剂,IC₅₀ 为 310 nM,为底物竞争性、选择性抑制剂。体外实验中,SIRT5 inhibitor 7 有效抑制 SIRT5 酶活性,并调控蛋白琥珀酰化水平[1]。 |
| 体内活性 | 在LPS和盲肠结扎穿孔(CLP)诱导的脓毒性急性肾损伤(AKI)小鼠模型中,SIRT5 inhibitor 7 显著改善肾功能、减轻组织损伤,并抑制肾组织中促炎因子的释放[1]。 |
| 分子量 | 582.12 |
| 分子式 | C28H32ClN7O3S |
| CAS No. | 2951090-00-7 |
| Smiles | N(CCCNC(NCCC(O)=O)=S)C=1C(C(=O)N2C[C@H](CC2)C3=CC=CC=C3)=CN=C(NC4=C(Cl)C=CC=C4)N1 |
| 存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容